Vaccination strategies are also promising: a phase IIB/III study is currently ongoing to evaluate the efficacy of TG4010 (recombinant vaccinia virus of the Ankara strain), a genetically modified virus expressing both mucinous glycoprotein 1 (MUC1) and IL-2, in advanced NSCLC patients [17]. This evidence concerns the gene IL2 and non-small cell lung carcinoma.